Bioceres Crop Solutions Statistics
Total Valuation
BCBA:BIOX has a market cap or net worth of ARS 367.39 billion. The enterprise value is 717.01 billion.
Market Cap | 367.39B |
Enterprise Value | 717.01B |
Important Dates
The last earnings date was Monday, May 12, 2025.
Earnings Date | May 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | -4.74% |
Shares Change (QoQ) | -0.59% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 32.63M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 39.94 |
PS Ratio | 0.89 |
PB Ratio | 0.99 |
P/TBV Ratio | 16.23 |
P/FCF Ratio | 8.75 |
P/OCF Ratio | 7.39 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.47, with an EV/FCF ratio of 17.09.
EV / Earnings | -73.78 |
EV / Sales | 1.56 |
EV / EBITDA | 13.47 |
EV / EBIT | 28.62 |
EV / FCF | 17.09 |
Financial Position
Current Ratio | n/a |
Quick Ratio | n/a |
Debt / Equity | 0.82 |
Debt / EBITDA | 6.23 |
Debt / FCF | 7.30 |
Interest Coverage | 0.88 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | 2.27% |
Return on Capital Employed (ROCE) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.47% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -60.47% |
50-Day Moving Average | 5,452.20 |
200-Day Moving Average | 7,903.18 |
Relative Strength Index (RSI) | 60.54 |
Average Volume (20 Days) | 35,972 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 4.30 |
Income Statement
In the last 12 months, BCBA:BIOX had revenue of ARS 411.31 billion and -9.72 billion in losses. Loss per share was -154.77.
Revenue | 411.31B |
Gross Profit | 161.29B |
Operating Income | 24.05B |
Pretax Income | -20.14B |
Net Income | -9.72B |
EBITDA | 44.08B |
EBIT | 24.05B |
Loss Per Share | -154.77 |
Balance Sheet
The company has 33.48 billion in cash and 306.52 billion in debt, giving a net cash position of -273.05 billion.
Cash & Cash Equivalents | 33.48B |
Total Debt | 306.52B |
Net Cash | -273.05B |
Net Cash Per Share | n/a |
Equity (Book Value) | 371.65B |
Book Value Per Share | 5,297.02 |
Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 49.75 billion and capital expenditures -7.78 billion, giving a free cash flow of 41.96 billion.
Operating Cash Flow | 49.75B |
Capital Expenditures | -7.78B |
Free Cash Flow | 41.96B |
FCF Per Share | n/a |
Margins
Gross margin is 39.21%, with operating and profit margins of 5.85% and -2.36%.
Gross Margin | 39.21% |
Operating Margin | 5.85% |
Pretax Margin | -4.90% |
Profit Margin | -2.36% |
EBITDA Margin | 10.72% |
EBIT Margin | 5.85% |
FCF Margin | 10.20% |
Dividends & Yields
BCBA:BIOX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 4.74% |
Shareholder Yield | n/a |
Earnings Yield | -2.65% |
FCF Yield | 11.42% |
Stock Splits
The last stock split was on January 24, 2024. It was a forward split with a ratio of 2.
Last Split Date | Jan 24, 2024 |
Split Type | Forward |
Split Ratio | 2 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |